Izifo ze-Autoimmune, ezizintlobo ngeentlobo kwaye zizifo ezixhaphakileyo kunye neziyingozi, yenye yeendlela ezibalulekileyo zophuhliso lwangoku lwamachiza.I-JAK-STAT yenye yeendlela ezimbalwa ze-immunomodulatory eziye zabonakaliswa, ngakumbi i-JAK inhibitors.Amachiza amaninzi,njenge tofacitinib, ziye zathengiswa ehlabathini lonke.

Ithagethi ye-JAK iphuhliswe ngaphantsi kweminyaka engama-20, kodwa ngoku phantse iintlobo ezisi-7 zamkelwe ukuba zithengiswe.Izalathisi ikakhulu ngamathumba kunye nezifo ezizikhuselayo ngokwasemzimbeni, kwaye ezonalathisi zisulungekileyo ngakumbi zizifo zomongo wethambo kunye ne-rheumatoid arthritis.Oku kulandelayo kugxininise kwi-JAK inhibitor yokuqala (tofacitinib) yonyango lwe-rheumatoid arthritis.

I-Tofacitinib yi-molecule yomlomo encinci ye-JAK inhibitor eyenziwe nguPfizer.Inokhetho oluhle lweJAK.NgoNovemba ka-2012, i-US FDA yavuma i-tofacitinib citrate yonyango lwe-methotrexate enganelanga okanye impendulo enganyamezeliyo kunyango.Le mveliso yi-JAK inhibitor yokuqala evunywe yi-FDA yonyango lwe-rheumatoid arthritis.Okwangoku, ukongeza kwimiqondiso evunyiweyo, i-tofacitinib ikwavavanyelwa ukusebenza kwayo kwi-ankylosing spondylitis, i-atopic dermatitis, i-keratoconjunctivitis sicca kunye nesifo sikaCrohn.Ngokuphathelele kwintengiso yehlabathi, intengiso yonyaka ye-tofacitinib ngo-2017 ibingaphezulu kwe-1 yeebhiliyoni zeedola, kwaye intengiso yonyaka ngo-2019 ifikelele kwi-2.242 yeebhiliyoni zeedola.

Iindlela ezahlukeneyo zokwenziwa ziya kuba nefuthe elikhulu kwisivuno kunye nomgangatho we-APIs.Ukwenziwa kwethu kwe-tofacitinib citrate kuthintela indlela enelungelo elilodwa lomenzi wechiza.Indlela yokwenziwa idinga ixabiso eliphantsi lempahla ekrwada, isivuno esikhulu, ukungcola okukodwa kunye nokucoceka kunokulawulwa ngaphakathi koluhlu olufanelekileyo, okanye lunokwenziwa ngokwezifiso ngabathengi.Ngaloo ndlela sivumele ukuba sibe nenzuzo ebonakalayo kwimarike.Ngoku umthamo wethu unokuba yi-50kg ngenyanga, kunye ne-tofacitinib citrate esele ithunyelwe e-USA, Mexico, Franch, Bangladesh, njl.